8月7日，Natera盘后上涨8.15%，报288.49美元/股，成交额2227.51万美元。消息面上，公司于8月6日盘后发布最新季度财报。此前市场一致预期本季度营收为6.61亿美元，同比增长38.72%，调整后每股亏损0.49美元。值得注意的是，公司此前已将全年营收指引上调至27.4亿至28.2亿美元，显著高于市场预期的26.7亿美元，且前两个季度营收均大幅超出预期（Q4超12.34%、Q1超约13%）。近期公司核心产品Signatera接连获得欧盟IVDR认证、日本PMDA批准及NCCN一类推荐，同时与Aveta Biomics、Eledon等达成多项三期临床合作，持续巩固MRD检测领域领导地位。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.